Crossmark

Response to the Letter from Garcia-Montojo and colleagues concerning our paper entitled, Quantitative analysis of human endogenous retrovirus-K transcripts in postmortem premotor cortex fails to confirm elevated expression of HERV-K RNA in amyotrophic lateral sclerosis

Crossref DOI link: https://doi.org/10.1186/s40478-019-0756-9

Published Online: 2019-07-03

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Garson, Jeremy A. https://orcid.org/0000-0003-0553-0126
Usher, Louise

Al-Chalabi, Ammar

Huggett, Jim

Day, Edmund F.

McCormick, Adele L.
License Information

Text and Data Mining valid from 2019-07-03

Version of Record valid from 2019-07-03
More Information

Article History

Received: 19 June 2019

Accepted: 19 June 2019

First Online: 3 July 2019

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: AAC reports consultancies for Biogen Idec, Mitsubishi-Tanabe Pharma, Cytokinetics Inc., Treeway, Chronos Therapeutics Inc., GSK and OrionPharma in the past 5 years, and was Chief Investigator for clinical trials from Cytokinetics Inc. and OrionPharma. AAC is a collaborator in a Phase 2 clinical trial of Triumeq, an antiretroviral drug, in ALS. None of the other co-authors report any competing interests.

Document is current

Any future updates will be listed below